{"filing":{"accession_number":"0001714899-26-000074","cik":"0001714899","ticker":"DNLI","company_name":"Denali Therapeutics Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"dnli-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000074/dnli-20260603.htm"},"events":[{"id":7004,"run_id":6144,"accession_number":"0001714899-26-000074","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the results of Denali Therapeutics' June 3, 2026 annual meeting of stockholders, including voting outcomes on three proposals: election of three Class III directors (with specific vote tallies for each nominee), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of executive compensation. The filing directly matches the shareholder_vote_results event type and is material to investors assessing board composition and governance.","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4563,"accession_number":"0001714899-26-000074","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Denali Therapeutics' June 3, 2026 annual meeting of stockholders, including voting outcomes on three proposals: election of three Class III directors (with specific vote tallies for each nominee), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of executive compensation. The filing directly matches the shareholder_vote_results event type and is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:27:51.659185+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4563,"accession_number":"0001714899-26-000074","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Denali Therapeutics' June 3, 2026 annual meeting of stockholders, including voting outcomes on three proposals: election of three Class III directors (with specific vote tallies for each nominee), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of executive compensation. The filing directly matches the shareholder_vote_results event type and is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:27:51.659185+00:00","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-06-04"}]}